Post hoc analyses identified potential confounders influencing blood pressure responses in both sham control and RDN groups in the SYMPLICITY HTN-3 trial.
What are the predictors of blood pressure response to RDN versus sham control in patients with resistant hypertension?
Patients with resistant hypertension
RDN (renal denervation)
Sham control
Blood pressure responsesurrogate
Post hoc analyses of the SYMPLICITY HTN-3 trial identified potential confounding factors that may explain the unexpected blood pressure responses to renal denervation, informing future trial designs.
Absolute Event Rate: 0% vs 0%
Post hoc analyses, although derived from limited patient cohorts, reveal several potential confounding factors that may partially explain the unexpected blood pressure responses in both the sham control and RDN groups. These hypothesis-generating data further inform the design of subsequent research to evaluate the potential role of RDN in the treatment of resistant hypertension. CLINICALTRIALS.GOV IDENTIFIER: NCT01418261.
Building similarity graph...
Analyzing shared references across papers
Loading...
David E. Kandzari
Interventional Cardiology
Deepak L. Bhatt
Mount Sinai Health System
Sandeep Brar
Medtronic (Ireland)
European Heart Journal
Harvard University
University of Pennsylvania
University of Chicago
Building similarity graph...
Analyzing shared references across papers
Loading...
Kandzari et al. (Sun,) reported a other. Post hoc analyses identified potential confounders influencing blood pressure responses in both sham control and RDN groups in the SYMPLICITY HTN-3 trial.
synapsesocial.com/papers/697e18711f386ba20591f0d4 — DOI: https://doi.org/10.1093/eurheartj/ehu441
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: